M. Condomines

发表

Abstract 3499: CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma

M. Sadelain, R. Benjamin, M. Condomines, 2012 .

for Adoptive Immunotherapy Patients with Multiple Myeloma: A Window Melphalan-Induced Lymphodepletion in throughout the High-Dose Increased Plasma-Immune Cytokines

J. Rossi, B. Klein, M. Condomines, 2009 .

Increased Plasma-Immune Cytokines throughout the High-Dose Melphalan-Induced Lymphodepletion in Patients with Multiple Myeloma: A Window for Adoptive Immunotherapy

J. Rossi, B. Klein, M. Condomines, 2009, The Journal of Immunology.

Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma.

G. Requirand, T. Rème, B. Klein, 2022 .

Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma 1

G. Requirand, B. Klein, D. Hose, 2009 .

This information is current as Granulocyte Colony-Stimulating Factor High-Dose Cyclophosphamide and in Stem Cell Autografts by Mobilization with Functional Regulatory T Cells Are Collected

K. Tarte, G. Requirand, J. Rossi, 2017 .

Functional Regulatory T Cells Are Collected in Stem Cell Autografts by Mobilization with High-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor1

K. Tarte, G. Requirand, J. Rossi, 2006, The Journal of Immunology.

Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor.

K. Tarte, G. Requirand, J. Rossi, 2006, The Journal of Immunology.

Induction of angiogenesis by normal and malignant plasma cells.

T. Rème, J. Rossi, B. Klein, 2009, Blood.

In vitro expansion of gamma delta T cells with anti‐myeloma cell activity by Phosphostim and IL‐2 in patients with multiple myeloma

T. Rème, J. Rossi, B. Klein, 2007, British journal of haematology.

Determined by Microarray Analysis Expression Patterns and Prognosis Value Cancer/Testis Genes in Multiple Myeloma:

J. D. Vos, P. Raynaud, V. Pantesco, 2007 .

Tolerance induction by allogeneic hematopoietic stem cells.

M. Sadelain, M. Condomines, 2011, Cell stem cell.

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

Michel Sadelain, Michael Bachmann, M. Sadelain, 2012, Nature Biotechnology.

Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition

M. Sadelain, R. Benjamin, M. Condomines, 2015, PloS one.

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.

M. Sadelain, M. Condomines, Gertrude Gunset, 2015, Cancer cell.

Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma1

Hartmut Goldschmidt, Dirk Hose, Bernard Klein, 2009, The Journal of Immunology.

Cancer-Testis Antigens in Multiple Myeloma PCR Analyses Identify Novel Potential Gene Expression Profiling and Real-Time

G. Requirand, T. Rème, B. Klein, 2009 .

Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis1

P. Raynaud, V. Pantesco, T. Rème, 2007, The Journal of Immunology.

B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.

K. Tarte, J. Rossi, B. Klein, 2007, Experimental hematology.

Identification of HLA‐A2 restricted T‐cell epitopes within the conserved region of the immunoglobulin G heavy‐chain in patients with multiple myeloma

B. Klein, D. Hose, H. Goldschmidt, 2008, European journal of haematology.

Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

B. Klein, D. Hose, H. Goldschmidt, 2006, Experimental hematology.

Melan-A/MART1 Analog Peptide Triggers Anti-myeloma T-cells Through Crossreactivity With HM1.24

B. Klein, D. Hose, H. Goldschmidt, 2009, Journal of immunotherapy.